Activation of Signal Transducer and Activator of Transcription-5 in Prostate Cancer Predicts Early Recurrence

Purpose: We have shown previously that the signal transducer and activator of transcription-5 (Stat5) is a critical survival factor in human prostate cancer cells. In addition, we recently showed that Stat5 is activated at a high level, particularly in high-grade human prostate cancers. Here, we investigated whether activation of Stat5 in prostate cancer was linked to clinical outcome with disease recurrence as end point. Experimental Design: Immunohistochemistry was used to detect active, nuclear Stat5 in 357 paraffin-embedded prostate cancer specimens on a tissue microarray with clinical follow-up data. Stat5 activation status in prostate cancer specimens was analyzed by univariate and multivariate survival analysis to determine whether activation of Stat5 predicts earlier prostate cancer recurrence. Separate sets of statistical analysis were done for all patients regardless of Gleason grade and for patients with prostate cancer of intermediate Gleason grades (3 and 4). Results and Conclusions: Stat5 activation in prostate cancer was associated with early disease recurrence (P = 0.0399). Importantly, active Stat5 also predicted shorter progression-free survival in intermediate Gleason grade prostate cancers (P = 0.0409). Stat5 activation remained an independent prognostic marker after adjusting for Gleason grade, pT stage, perineural invasion, or seminal vesicle infiltration in all patients (P = 0.0565) and in Gleason grade 3 or 4 patients (P = 0.0582). The results of this work also confirmed our previous finding of association of Stat5 activation with a high histologic grade of prostate cancer (R = 0.11, P = 0.033). In summary, our study shows that active Stat5 distinguished prostate cancer patients whose disease is likely to progress earlier; therefore, active Stat5 may be a useful marker for selection of more individualized treatment. The results of this study need to be validated in a large prospective cohort.

[1]  J. Xie,et al.  Activation of Signal Transducer and Activator of Transcription 5 in Human Prostate Cancer Is Associated with High Histological Grade , 2004, Cancer Research.

[2]  J. Xie,et al.  Signal transducer and activator of transcription-5 activation and breast cancer prognosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  E. Gehan,et al.  Long‐term outcomes after radical prostatectomy performed in a community‐based health maintenance organization , 2004, Cancer.

[4]  N. Greenberg,et al.  Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system. , 2003, Cancer research.

[5]  M. LeBaron,et al.  Inhibition of Transcription Factor Stat5 Induces Cell Death of Human Prostate Cancer Cells* , 2003, Journal of Biological Chemistry.

[6]  L. Bubendorf,et al.  Tissue microarray analysis reveals prognostic significance of syndecan‐1 expression in prostate cancer , 2003, The Prostate.

[7]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[8]  M. Nevalainen,et al.  Basal activation of transcription factor signal transducer and activator of transcription (Stat5) in nonpregnant mouse and human breast epithelium. , 2002, Molecular endocrinology.

[9]  M. Nevalainen,et al.  PRL signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro. , 2002, Endocrinology.

[10]  M. Nevalainen,et al.  PRL Signal Transduction in the Epithelial Compartment of Rat Prostate Maintained as Long-Term Organ Cultures in Vitro. , 2002, Endocrinology.

[11]  J. Ihle.  The Stat family in cytokine signaling. , 2001, Current opinion in cell biology.

[12]  M. Nevalainen,et al.  Prolactin Is a Survival Factor for Androgen-Deprived Rat Dorsal and Lateral Prostate Epithelium in Organ Culture1. , 1999, Endocrinology.

[13]  M. Nevalainen,et al.  Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture. , 1999, Endocrinology.

[14]  A. Bartke,et al.  Neuroendocrine and reproductive functions in male mice with targeted disruption of the prolactin gene. , 1998, Endocrinology.

[15]  B. Groner,et al.  p53 suppresses cytokine induced, Stat5 mediated activation of transcription , 1998, Molecular and Cellular Endocrinology.

[16]  O. Isaksson,et al.  Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. , 1998, Endocrinology.

[17]  M. Nevalainen,et al.  Androgen‐dependent expression of prolactin in rat prostate epithelium in vivo and in organ culture , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[19]  M. Nevalainen,et al.  Prolactin and prolactin receptors are expressed and functioning in human prostate. , 1997, The Journal of clinical investigation.

[20]  M. Nevalainen,et al.  Expression and hormone regulation of prolactin receptors in rat dorsal and lateral prostate. , 1996, Endocrinology.

[21]  Nancy Reid,et al.  Statistical Theory and Modeling: In Honour of Sir David Cox, FRS. , 1992 .

[22]  M. Nevalainen,et al.  Estrogen and prolactin regulation of rat dorsal and lateral prostate in organ culture. , 1991, Endocrinology.

[23]  I. Hart,et al.  Tumor cell progression and differentiation in metastasis. , 1991, Seminars in cancer biology.

[24]  K. Yasuda,et al.  Transformation of cell adhesion properties by exogenously introduced E-cadherin cDNA , 1987, Nature.

[25]  E. Gehan.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES. , 1965, Biometrika.

[26]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .